Launch of Nerivio Marks Company’s Foray into Digital Therapeutics, Offering Novel Relief for Migraine Sufferers
Dr. Reddy’s Laboratories, a prominent pharmaceutical company based in Hyderabad, has announced the launch of its migraine management wearable device, Nerivio, in Germany through its subsidiary Betapharm. This strategic move signifies the company’s entry into the realm of digital therapeutics in Europe, aiming to revolutionize migraine treatment and provide innovative solutions for patients.
Nerivio, which has already received approval from the US Food and Drug Administration (USFDA), has now obtained CE marking certification in Europe, making it accessible to a wider audience. The device, designed to alleviate migraine symptoms, represents a significant advancement in the management of this debilitating condition.
In a statement, Dr. Reddy’s Laboratories highlighted the success of Nerivio in India since its launch last year. With endorsements from neurologists and positive feedback from migraine patients, Nerivio has emerged as a promising solution for addressing the unmet clinical needs of individuals living with migraine.
MV Ramana, CEO of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, expressed confidence in Nerivio’s ability to make a meaningful impact on migraine management. “We believe this product meets a genuine unmet clinical need among migraine patients, and has the potential to reduce pill burden in migraine,” he stated.
The introduction of Nerivio in Europe represents a significant milestone for Dr. Reddy’s Laboratories as it continues to expand its global footprint and enhance its portfolio of innovative healthcare solutions.
